Bengal Physician Journal

Register      Login

VOLUME 10 , ISSUE 2 ( May-August, 2023 ) > List of Articles

CASE REPORT

Incretin-based Antidiabetic Therapy and Pancreatitis: A Case Series

Arijit Kayal, Dipan Saha, Anindya Karmakar, Debarati Bhar, Pranesh Sarkar

Keywords : Acute pancreatitis, Case report, Diabetes mellitus, GLP-1 agonist

Citation Information : Kayal A, Saha D, Karmakar A, Bhar D, Sarkar P. Incretin-based Antidiabetic Therapy and Pancreatitis: A Case Series. Bengal Physician Journal 2023; 10 (2):69-70.

DOI: 10.5005/jp-journals-10070-8012

License: CC BY-NC 4.0

Published Online: 07-08-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly referred to as gliptins, are a class of oral antihyperglycemic agents used for the management of type 2 diabetes mellitus. They work by inhibiting the enzyme DPP-4, which leads to increased levels of incretin hormones such as glucagon-like peptide-1 (GLP-1). On the contrary, glucagon-like peptide 1 receptor agonists (GLP-1RA) are the newest treatment for diabetes mellitus (DM). Many of these incretin-based agents have shown positive results in their respective cardiovascular outcome trials (CVOT). Acute pancreatitis is a condition that has been a subject of concern in relation to incretin-based therapies, as reported in some randomized clinical trials. Here, we present three such cases of pancreatitis related to this antidiabetic therapy.


HTML PDF Share
  1. Tkáč I, Raz I. Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 2017;40(2):284–286. DOI: 10.2337/dc15-1707.
  2. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141(1):150–156. DOI: 10.1053/j.gastro.2011. 02.018.
  3. Roshanov PS, Dennis BB. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. Diabetes Res Clin Pract 2015;110(3):e13–17. DOI: 10.1016/j.diabres. 2015.10.014.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.